Media Articles Related to Amevive (Alefacept)
CHMP Backs Secukinumab, Apremilast for Psoriasis
Source: Medscape Medical News Headlines [2014.11.21]
The European Medicines Agency committee has recommended secukinumab and apremilast for moderate to severe plaque psoriasis and apremilast for active psoriatic arthritis.
Positive results from second pivotal Phase 3 study of Brodalumab in patients with moderate-to-severe plaque psoriasis announced
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.11.13]
Amgen and AstraZeneca has announced that AMAGINE-3(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis...
Brodalumab Beats Stelara in Psoriasis Trial, Sponsors Say
Source: MedPage Today Dermatology [2014.11.11]
(MedPage Today) -- More patients achieve total plaque clearance in topline results.
New research reveals true impact of psoriasis
Source: Dermatology News From Medical News Today [2014.11.03]
Innovative research published in the latest edition of the British Journal of Dermatology reveals the causes behind the emotional distress experienced by people with psoriasis.
Lesion-healing mechanism identified in psoriasis
Source: Dermatology News From Medical News Today [2014.10.29]
A UC Irvine-led study has revealed the underlying genetic factors that help repair skin lesions caused by psoriasis, which could engender new methods of controlling the lingering condition.Dr.
Published Studies Related to Amevive (Alefacept)
Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. [2009.12]
BACKGROUND: Evidence from clinical trials supports the use of alefacept for the treatment of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities. OBJECTIVE: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, phase IV Canadian registry of psoriasis patients treated with alefacept... CONCLUSION: Alefacept is commonly added to other antipsoriatic therapies in a broad population of real-world chronic plaque psoriasis patients in Canada and may allow for dosage reduction or discontinuation of concomitant systemic agents or phototherapy.
Efficacy outcomes in patients using alefacept in the AWARE study. [2009.12]
BACKGROUND: Alefacept has demonstrated efficacy in clinical trials of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities such as phototherapy. OBJECTIVE: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, phase IV Canadian registry of psoriasis patients treated with alefacept... CONCLUSION: A single course of alefacept therapy improved outcomes in this broad population of real-world chronic plaque psoriasis patients.STUDY LIMITATIONS:The limitations of this study include its nonrandomized, noncontrolled, noncomparative design, which allowed multiple different treatment approaches across all patients. The rating scales used in this study have not been previously validated, and ranges were assigned to baseline control and response data that are not specifically defined. Clinicians did not receive specific training in using these scales; therefore, interrater variability could not be assessed.
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. [2009.11]
OBJECTIVE: To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA)...
Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. [2009.03]
BACKGROUND: A single course of alefacept intramuscularly in combination with methotrexate (MTX) was effective in treating both psoriasis and psoriatic arthritis (PsA). OBJECTIVE: We sought to determine the efficacy and safety of an additional course of alefacept intramuscularly in combination with MTX in patients with PsA... CONCLUSIONS: Patients with psoriasis and PsA on stable doses of MTX derive benefit for both conditions from one or more courses of alefacept, with further benefit in PsA apparent after a second course of treatment. No additional toxicity was observed.
Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. [2007.08]
OBJECTIVE: To determine whether the addition of 311-nm narrowband UV-B (NB UV-B) phototherapy accelerates and improves the therapeutic efficacy of alefacept, a biological antipsoriatic drug approved for the treatment of moderate to severe psoriasis... CONCLUSIONS: In this randomized half-side comparison of alefacept with and without phototherapy for psoriasis, alefacept with NB UV-B phototherapy accelerated and improved the clearance of psoriasis. This suggests a promising future for this combination as antipsoriatic therapy.
Clinical Trials Related to Amevive (Alefacept)
Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Recruiting]
The study is a prospective, multi-centre, observational study designed to assess the
long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic
AMEVIVEďż˝ Pregnancy Registry [Recruiting]
This is an observational, exposure-registration and follow-up study, to be conducted in the
United States (US). The AMEVIVEŽ Pregnancy Exposure Registry is designed to monitor
pregnant subjects and fetuses exposed to AMEVIVEŽ in order to detect any potential increase
in the risk of major birth defects.
The AMEVIVEŽ Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development
and will be managed by INC Research. The Registry will be monitored by an independent
Advisory Committee of external experts in relevant specialties of teratology, epidemiology,
maternal and fetal medicine, and infectious disease medicine (external member details
available upon request).
Long-Term One Year Use of Alefacept (Ameviveďż˝) in Moderate to Severe Chronic Plaque Type Psoriasis [Recruiting]
The purpose of this research study is to see how well the medication Alefacept (AmeviveŽ)
works for continuous treatment of chronic plaque psoriasis. The US Food and Drug
Administration (FDA) has approved Alefacept in an intermittent dosage schedule of 15 mg
weekly injection for 12 weeks followed by 12 weeks off treatment.
Inducing Remission in Type 1 Diabetes With Alefacept [Recruiting]
The purpose of this trial is to test whether a drug called alefacept will slow or halt
destruction of the beta cells in the pancreas. If the destruction of the beta cells is
stopped the patients might be able to produce insulin on their own longer which could stop
or slow the progression of their type 1 diabetes.
This proposal is for a multi-center prospective, placebo-controlled, double-blind and
randomized, controlled trial to investigate the ability of alefacept to protect residual
beta cells in adolescents and young adults with newly diagnosed Type 1 diabetes mellitus
from ongoing autoimmune destruction.
Community Based Trial for AMEVIVEŽ [Completed]
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
Reports of Suspected Amevive (Alefacept) Side Effects
OFF Label USE (14),
Diabetes Mellitus (8),
Kidney Transplant Rejection (7),
Antibody Test Positive (4),
Myocardial Infarction (3),
Cardiac Failure Congestive (3),
Infectious Peritonitis (2),
Cellulitis (2), more >>